The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
Official Title: A Phase I Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
Study ID: NCT00625768
Brief Summary: To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose of AS1409 in single and repeated doses.
Detailed Description: * To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose (MTD) of AS1409 in single and repeated doses. * To determine biological responses to AS1409, including interferon-γ and IP-10 circulating concentrations. * To determine preliminary pharmacokinetics of AS1409. * To determine the immunogenicity of AS1409 * To explore the anti-tumour activity of AS1409.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Auckland Medical School, Auckland, , New Zealand
Waikato DHB, Hamilton, , New Zealand
Guys Hospital, London, , United Kingdom
Charing Cross Hospital, London, , United Kingdom
Name: James Spicer, MD
Affiliation: Kings College School of Medicine
Role: PRINCIPAL_INVESTIGATOR